Aleglitazar is a peroxisome proliferator-activated receptor agonist (hence a PPAR modulator) with affinity to PPARα and PPARγ, which was under development by Hoffmann–La Roche for the treatment of type II diabetes. It is no longer in phase III clinical trials.
{{chembox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 477246742 | ImageFile = Aleglitazar.svg | ImageClass = skin-invert-image | ImageSize = 200px | PIN = (2S)-2-Methoxy-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl}propanoic acid | OtherNames = Ro-0728804, R-1439 |Section1= |Section2= |Section3= }}
Aleglitazar is a peroxisome proliferator-activated receptor agonist (hence a PPAR modulator) with affinity to PPARα and PPARγ, which was under development by Hoffmann–La Roche for the treatment of type II diabetes. It is no longer in phase III clinical trials.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).